Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells

Endocrine-Related Cancer

Volumn 12, Issue 2, 2005, Pages 351-365

  Dwivedi, Prem P ^a   Anderson, Paul H ^b   Omdahl, John L ^c   Grimes, H Leighton ^d   Morris, Howard A ^b   May, Brian K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b HANSON INSTITUTE   (Australia)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CYTOCHROME P450; CYTOCHROME P450 27B1; GENE PRODUCT; HISTONE DEACETYLASE; ONCOPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GROWTH FACTOR INDEPENDENT 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; ELECTROPHORETIC MOBILITY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; 5' FLANKING REGION; BINDING SITES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; SEQUENCE DELETION; TRANSCRIPTION FACTORS;

EID: 21244454023     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00920     Document Type: Article

References (49)

1. Adams JS & Gacad MA 1985 Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. The Journal of Experimental Medicine 161 755-765.
2. Anderson PH, May BK & Morris HA 2003 Vitamin D metabolism: new concepts and clinical implications. Clinical Biochemist Reviews 24 13-26.
3. Andrews NC & Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Research 19 2499.
4. Bahr A, Hankeln T, Fiedler T, Hegemann J & Schmidt ER 1999 Molecular analysis of METTL1, a novel human methyltransferase-like gene with a high degree of phylogenetic conservation. Genomics 57 424-428.
5. Blutt SE, McDonnell TJ, Polek TC & Weigel NC 2000 Calcitriol induced apoptosis in LNCaP cells is blocked by over expression of Bcl-2. Endocrinology 141 10-17.
6. Carlberg C & Polly P 1998 Gene regulation by vitamin D3. Critical Reviews In Eukaryotic Gene Expression 8 19-42.
7. Chen TC & Holick MF 2003 Vitamin D and prostate cancer prevention and treatment. Trends Endocrinology and Metabolism 14 423-430.
8. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL & Holick MF 2000 The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha, 25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clinical Cancer Research 6 901-908.
9. Chen TC, Wang L, Whitlatch LW, Flanagan JN & Holick MF 2003 Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. Journal of Cellular Biochemistry 88 315-322.
10. Christakos S, Raval-Pandya M, Wernyj RP & Yang W 1996 Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. The Biochemical Journal 316 361-371.
11. Doan LL, Porter SD, Duan Z, Flubacher MM, Montoya D, Tsichlis PN, Horwitz M, Gilks CB & Grimes HL 2004 Targeted transcriptional repression of Gfil by GFI1 and GFI1B in lymphoid cells. Nucleic Acids Research 32 2508-2519.
12. Duan Z & Horwitz M 2003 Targets of the transcriptional repressor oncoprotein GFI-1. PNAS 100 5932-5937.
13. Dwivedi PP, Omdahl JL, Kola I, Hume DA & May BK 2000 Regulation of rat cytochrome P450C24 (CYP24) gene expression: evidence for functional cooperation of Ras-activated Ets transcription factors with the vitamin D receptor in 1,25-dihydroxyvitamin D(3)-mediated induction. Journal of Biological Chemistry 275 47-55.
14. Dwivedi PP, Hii CST, Ferrante A, Tan J, Der CJ, Omdahl JL, Morris HA & May BK 2002 Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450c24 (CYP24) promoter: Specific functions for ERK1/ERK2 and ERK5. Journal of Biological Chemistry 277 29643-29653.
15. Ebert R, Jovanovic M, Ulmer M, Schneider D, Meissner-Weigl J, Adamski J & Jakob F 2004 Down-regulation by nuclear factor kB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter. Molecular Endocrinology 18 2440-2450.
16. Gao XH, Dwivedi PP, Choe S, Alba F, Morris HA, Omdahl JL & May BK 2002 Basal and parathyroid hormone induced expression of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene promoter in kidney AOK-B50 cells: role of Sp1, Ets and CCAAT box protein binding sites. The International Journal of Biochemistry and Cell Biology 34 921-930.
17. Gilks CB, Bear SE, Grimes HL & Tsichlis PN 1993 Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. Molecular and Cellular Biology 13 1759-1768.
18. Grimes HL, Chan TO, Zweidler-McKay PA, Tong B & Tsichlis PN 1996a The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by interleukin-2 withdrawal. Molecular and Cellular Biology 16 6263-6272.
19. Grimes HL, Gilks CB, Chan TO, Porter S & Tsichlis PN 1996b The Gfi-1 protooncoprotein represses Bax expression and inhibits T-cell death. PNAS 93 14569-14573.
20. Gross C, Stamey T, Hancock S & Feldman D 1998 Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). The Journal of Urology 159 2035-2039.
21. Gulliford T, English J, Colston KW, Menday P, Moller S & Coombes RC 1998 A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. British Journal of Cancer 78 6-13.
22. Guyton KZ, Kensler TW & Posner GH 2003 Vitamin D and Vitamin D analogs as cancer chemopreventive agents. Nutrition Reviews 61 227-238.
23. Hewison M & O'Riordan JL 1994 Hormone-nuclear receptor interactions in health and disease. Vitamin D resistance. Bailliere's Clinical Endocrinology and Metabolism 8 305-315.
24. Howard GA, Turner RT, Sherrard DJ & Baylink DJ 1981 Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. Journal of Biological Chemistry 256 7738-7740.
25. Hsu JY, Feldman D, McNeal JE & Peehl DM 2001 Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Research 61 2852-2856.
26. Issa LL, Leong GM & Eisman JA 1998 Molecular mechanism of vitamin D receptor action. Inflammation Research 47 451-475.
27. Jones G, Strugnell SA & DeLuca HF 1998 Current understanding of the molecular actions of vitamin D. Physiological Reviews 78 1193-1231.
28. Kazanjian A, Wallis D, Au N, Nigam R, Venken KJ, Cagle PT, Dickey BF, Bellen HJ, Gilks CB & Grimes HL 2004 Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. Cancer Research 64 6874-6882.
29. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D & Peehl DM 2004 Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Molecular and Cellular Endocrinology 221 67-74.
30. McGhee L, Bryan J, Elliott L, Grimes HL, Kazanjian A, Davis JN & Meyers S 2003 Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism. Journal of Cellular Biochemistry 89 1005-1018.
31. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE & Upadhya P 1992 The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Research 52 515-520.
32. Norman AW, Mizwicki MT & Okamura WH 2003 Ligand structure-function relationship in the vitamin D endocrine system from the perspective of drug development (including cancer treatment). Recent Results Cancer Research 164 55-82.
33. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas Koen, Endress G, Kunsch C & Libermann TA 2000 PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression. Journal of Biological Chemistry 275 1216-1225.
34. Omdahl JL, Bobrovnikova EA, Choe S, Dwivedi PP & May BK 2001 Overview of regulatory cytochrome P450 enzymes of the Vitamin D pathway. Steroids 66 381-389.
35. Omdahl JL, Morris HA & May BK 2002 Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annual Reviews of Nutrition 22 139-166.
36. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R & Trump DL 1995 Phase II trial of oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urology Oncology 1 195-198.
37. Peehl DM & Feldman D 2003 The role of vitamin D and retinoids in controlling prostate cancer progression. Endocrine Related Cancer 10 131-140.
38. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA & Feldman D 1994 Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Research 54 805-810.
39. Polek TC & Weigel NL 2002 Vitamin D and prostate cancer. Journal of Andrology 23 9-17.
40. Schwartz GG & Hulka BS 1990 Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Research 10 1307-1311.
41. Schwartz GG, Oeler TA, Uskokovic MR & Bahnson RR 1994 Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Research 14 1077-1081.
42. Schwartz GG, Wang MH, Zang M, Singh RK & Siegal GP 1997 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiology, Biomarkers and Prevention 6 727-732.
43. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL & Holick MF 1998 Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiology, Biomarkers and Prevention 7 391-395.
44. Tong B, Grimes HL, Yang TY, Bear SE, Qin Z, Du K, El-Deiry WS & Tsichlis PN 1998 The Gfi-1B proto-oncoprotein represses p21WAF1 and inhibits myeloid cell differentiation. Molecular and Cellular Biology 18 2462-2473.
45. Wallis D, Hamblen M, Zhou Y, Venken KJ, Schumacher A, Grimes HL, Zoghbi HY, Orkin SH & Bellen HJ 2003 The zinc finger transcription factor Gfi1, implicated in lymphomagenesis, is required for inner ear hair cell differentiation and survival. Development 130 221-232.
46. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF & Chen TC 2002 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. Journal of Steroid Biochemistry And Molecular Biology 81 135-140.
47. Yucel R, Kosan C, Heyd F & Moroy T 2004 Gfi1: green fluorescent protein knock-in mutant reveals differential expression and autoregulation of the growth factor independence 1 (Gfi1) gene during lymphocyte development. Journal of Biological Chemistry 279 40906-40917.
48. Zhuang SH & Burnstein KL 1998 Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139 1197-1207.
49. Zweidler-McKay PA, Grimes HL, Flubacher MM & Tsichlis PN 1996 Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. Molecular and Cellular Biology 16 4024-4034.